Reversal of Mechanical Dyssynchrony and Suppression of Atrial and Ventricular Ectopy With Left Bundle Branch Area Pacing.

Pacing Clin ElectrophysiolApr 11, 2026 (epub)
Case ReportCardiology

Muhammet Dural, Gurbet Ozge Yunus, Istiklal Ozkaya et al.

✦ AI-curated · Sources linked

Case in brief

A 57-year-old man with left bundle branch block–induced cardiomyopathy underwent left bundle branch area pacing (LBBAP). After pacing, left ventricular ejection fraction improved to 58% at 6 months, premature ventricular contractions fell to 200 per day, and supraventricular extrasystoles were no longer observed. The report describes improvement in mechanical synchrony alongside better ventricular function and suppression of both ventricular and atrial ectopy.

What made this case unusual

LBBAP was associated not only with improved ventricular function but also with suppression of both premature ventricular contractions and supraventricular extrasystoles.

Diagnostic / clinical pearl

In this case of LBBB-induced cardiomyopathy, LBBAP was followed by improved ejection fraction and reduced ventricular and supraventricular ectopy.

Source

PubMed · PMID 41964481

Published in Pacing Clin Electrophysiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.